Clinical Trial Update: Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and/or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A randomized Phase II trial evaluating ixabepilone alone versus ixabepilone plus cetuximab as first-line therapy for women with triple-negative locally advanced…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Ixabepilone (ixabepilone)

Snippet

Sponsor: R-Pharm | Conditions: Triple Negative Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-04-24